Log in to your Inderes Free account to see all free content on this page.
AcuCort
1 investor is following this company
AcuCort is a biotechnology company. The company has developed and commercializes the drug Zeqmelit, which is an oral film based on the cortisone substance dexamethasone, for quick availability and relief in, for instance, severe and acute allergic reactions. Zeqmelit is approved in Sweden, Denmark and Norway. The goal is global commercialization in the EU, USA and in selected key markets via licensees and distributors. The company has its headquarters in Lund.
ShowingAll content types
AcuCort AB: Very High Willingness to Pay for Zeqmelit® According to Publication in International Scientific Journal
AcuCort AB: Study on Patients' Willingness to Pay Published in an International Scientific Journal
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio